Skip to content

Study · Case report or series · n = 1 · 2020

2 results

Hypocalcemia secondary to hypomagnesemia in a patient on liraglutide.

Habnouny JEL, Jandou I, Latrech H, Bourgon C

Annals of medicine and surgery (2012)29 Oct 2020Cited by 4 (Europe PMC)

PMID33224484 (opens in a new tab)PMCIDPMC7662844 (opens in a new tab)DOI10.1016/j.amsu.2020.10.052 (opens in a new tab)PepBankPUB-33224484
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 73-year-old man with type 2 diabetes, severe diarrhea occurred under liraglutide treatment and the authors suggest it caused hypomagnesemia.

    In plain wordsIn one older man with type 2 diabetes on liraglutide, severe diarrhea occurred, and the authors link it to low magnesium.

    Peptide
    Liraglutide
    Outcome
    Not applicableSevere diarrhea under liraglutide
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Admitted to emergency for abdominal pain, severe diarrhea and episodes of tetany attacks.
    2 context sentences
    Summary · context
    which in turn was caused by severe diarrhea under treatment with Liraglutide.
    Summary · context
    A 73-year-old man with type 2 diabetes on Liraglutide with a history of coronary artery disease.
  2. 02HumanCase report or seriesSafety outcome

    In a 73-year-old man with type 2 diabetes on liraglutide, the authors suggest that hypocalcemia resulted from disrupted parathyroid hormone secretion caused by hypomagnesemia, which was caused by severe diarrhea under liraglutide.

    In plain wordsIn one older man on liraglutide, low calcium followed low magnesium, which the authors link to severe diarrhea under the drug.

    Peptide
    Liraglutide
    Outcome
    Not applicableHypomagnesemia and hypocalcemia
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Laboratory workup reveals hypomagnesemia, hypocalcemia and normal parathormone (PTH).
    2 context sentences
    Summary · context
    Strongly suggests that hypocalcemia resulted from a disruption of adequate parathyroid hormone secretion caused by hypomagnesemia which in turn was caused by severe diarrhea under treatment with Liraglutide.
    Summary · context
    A 73-year-old man with type 2 diabetes on Liraglutide with a history of coronary artery disease.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.